Business

Genzyme encouraged by MS drug

Genzyme, a Cambridge unit of French drug maker Sanofi SA, reported the publication of encouraging results from studies of Lemtrada, its drug candidate for treating multiple sclerosis.

Results were published in the online edition of the medical journal Lancet. Lemtrada is being reviewed by European regulators. At some point, Genzyme plans to seek Food and Drug Administration approval.

Advertisement

The studies published in Lancet were chaired by Alastair Compston, a professor of neurology at the UK’s University of Cambridge. A quote from Compston was included in the Genzyme press release.

Lemtrada has the potential to “become a transformative therapy amongst the various MS treatment options that are currently available,” he said.

In a statement, Genzyme chief executive David Meeker added: “Genzyme set a new standard by comparing Lemtrada exclusively to an approved treatment in all of our studies. Publication of these findings by the Lancet highlights the importance of these results to the MS community.”

Chris Reidy

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.